{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-033139","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2023-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.616117+00:00","generated_at":"2026-06-10T12:07:53.755051+00:00","sec_items":["1.01","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biotricity raises $2M via Series B Convertible Preferred Stock at $3.50 conversion price, 8% dividend","bullets":["Gross proceeds of $2,000,000 from sale of 220 Series B Preferred shares at $9,090.91 per share.","Series B Preferred carries 8% cumulative dividend, increasing to 15% upon a triggering event.","Initial conversion price set at $3.50 per share; alternate conversion at 80% of lowest VWAP.","Company may redeem shares at 110% of stated value; holders can force redemption upon a trigger event.","Institutional investor subject to 4.99% beneficial ownership cap; shareholder vote may be needed if conversion exceeds 19.9% of outstanding common."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-033139","json":"https://secwatch.observer/filing/0001493152-23-033139.json","markdown":"https://secwatch.observer/filing/0001493152-23-033139.md","text":"https://secwatch.observer/filing/0001493152-23-033139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223033139/0001493152-23-033139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223033139/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T12:07:53.755051+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8182ae89d9ab0f1259089d2a3495b94f0b9c9eab","claim":"BIOTRICITY INC. entered into Purchase Agreement with an institutional investor valued at $2,000,000 (effective 2023-09-19).","evidence_excerpt":"On September 19, 2023, Biotricity Inc. (the “Company”) entered into a security purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”) for the issuance and sale of 220 shares of the Company’s newly designated Series B Convertible Preferred Stock, $0.001 par value (the “Series B Preferred Stock”), at a purchase price of $9,090.91 per share of Preferred Stock, or gross proceeds of $2,000,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223033139/0001493152-23-033139-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional investor"},{"label":"Value","value":"$2,000,000"},{"label":"Effective","value":"2023-09-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}